Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. | ...

Newly recognized issues, including extreme fatigue with excessive weight reduction, bone loss, and abdominal pain, point to ...

Biotechs have faced several challenging years with slumping valuations and a competitive funding environment. However, the latest slew of ...

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

A group of advisers to the Food and Drug Administration said Roche Holding AG needs to study its blood cancer treatment in ...

Zealand Pharma A/S, a biotechnology company, has appointed Steven Johnson as Chief Development Officer.

Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

Pfizer and RemeGen's HER2 antibody-drug conjugate delivered positive phase 3 results in a bladder cancer trial in China. | ...

Precision Oncology market is set for strong growth through 2035, fueled by genomic advances, rising cancer cases, and increased use of targeted therapies.

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...

Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...

Roche Group said on Monday that it plans to invest more than $700 million in a new drug manufacturing facility in North ...